10 - Metabolic side effects and risk of cardiovascular disease  pp. 173-188

Metabolic side effects and risk of cardiovascular disease

By Jonathan M. Meyer, Donald C. Goff and Joseph P. McEvoy

Chapter Abstract

Multiple factors contribute to high levels of cardiovascular (CV) risk in schizophrenia patients including lifestyle habits. The additive CV effects of cigarette smoking, hypertension, total cholesterol, and high density lipoprotein (HDL) cholesterol have been found to predict the risk of major cardiac events over a 10 year period. These effects can be calculated with empirically derived CV risk algorithms. By the time the initial Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) analysis of metabolic syndrome prevalence was performed in 2005, there was already a signal that schizophrenia patients had 2-4 times higher prevalence than that expected from general population estimates. The CATIE schizophrenia trial data illustrate the possibility for improving metabolic health by switching patients from more offending medications, and for avoiding long-term CV consequences by preferential use of agents with metabolically benign profiles. Management of schizophrenia requires acknowledgment that CV disease remains a primary cause of excess mortality.


Keywords:

CATIE schizophrenia trial data; metabolic syndrome; cardiovascular risk; Clinical Antipsychotic Trials of Intervention Effectiveness; schizophrenia patient; National Cholesterol Education Program; high density lipoprotein;

10

Reference Title: References

Reference Type: reference-list

Lebowitz BD, Vitiello B and Norquist GS. Approaches to multisite clinical trials: The National Institute of Mental Health perspective. Schizophrenia Bulletin 2003;29:7–13.
Hotopf M, Churchill R and Lewis G. Pragmatic randomised controlled trials in psychiatry. British Journal of Psychiatry 1999;175:217–23.
March JS, Silva SG, Compton S, et al. The case for practical clinical trials in psychiatry. American Journal of Psychiatry 2005;162:836–46.
Tunis SR, Stryer DB and Clancy CM. Practical clinical trials: Increasing the value of clinical research for decision making in clinical and health policy. Journal of the American Medical Association 2003;290:1624–32.
Stroup TS and Geddes JR. Randomized controlled trials for schizophrenia: Study designs targeted to distinct goals. Schizophrenia Bulletin 2008;34:266–74.
Kemp R, Hayward P, Applewhaite G, et al. Compliance therapy in psychotic patients: Randomised controlled trial. British Medical Journal 1996;312:345–9.
Tessler RGG. Family Experiences Interview Schedule Toolkit. Cambridge, MA: Human Services Research Institute; 1995.
Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophrenia Bulletin 1993;19:609–18.
McEvoy JP, Apperson LJ, Appelbaum PS, et al. Insight in schizophrenia. Its relationship to acute psychopathology. The Journal of Nervous and Mental Disease 1989;177:43–7.
Appelbaum PS, Grisso T. MacArthur Competence Assessment Tool for Clinical Research. Sarasota, FL: Professional Resource Press; 2001.
Carpenter WT Jr, Gold JM, Lahti AC, et al. Decisional capacity for informed consent in schizophrenia research. Archives of General Psychiatry 2000;57:533–8.
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with schizophrenia. New England Journal of Medicine 2005;353:1209–23.

Reference Title: References

Reference Type: reference-list

Davis JM, Chen N and Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 2003;60:553–64.
Rosenheck RA, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S and Leslie D for the Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. Journal of the American Medical Association 2003;290:2693–702.
Dmitrienko A and Tamhane AC. Gatekeeping procedures with clinical trial applications. Pharmaceutical Statistics 2007;6:171–80.
Bauer P. Multiple testing in clinical trials. Statistics in Medicine 1991;10:871–90.
Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800–3.
Westfall PH, Tobias RD, Wolfinger RD and Hochberg Y. Multiple Comparisons and Multiple Tests Using the SAS System. Cary, NC: SAS Institute, Inc; 1999.
Lieberman JA, Stroup TS, McEvoy JP, et al; for the CATIE investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209–23.
Stroup TS, Lieberman JA, McEvoy JP, et al; for the CATIE Investigators. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: A CATIE study. American Journal of Psychiatry 2007;164:415–27.
McEvoy JP, Lieberman JA, Stroup TS, et al; for CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry 2006;163:600–10.
Stroup TS, Lieberman JA, McEvoy JP, et al; for the CATIE Investigators. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia after discontinuing a previous atypical antipsychotic. American Journal of Psychiatry 2006;163:611–22.
Stroup TS, Lieberman JA, McEvoy JP, et al; for the CATIE Investigators. Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research 2009;107:1–12.
Cox D. Regression models and life tables. Journal of the Royal Statistical Society 1972;B34:187–220.
Alison P. Survival Analysis Using the SAS® System: A Practical Guide. Cary, NC: SAS Institute, Inc; 1995.
Mallinckrodt CH, Clark WS and David SR. Accounting for dropout bias using mixed-effects models. Journal of Biopharmaceutical Statistics 2001;11:9–21.
Stokes ME, Davis CS and Koch GG. Categorical Data Analysis using the SAS® System. Cary, NC: SAS Institute, Inc; 2000.
Rubin DB. Multiple imputation after 18+ years. Journal of the American Statistical Association 1996;91:473–89.
Rosenheck RA, Leslie D, Sindelar J, et al. Cost-effectiveness of second generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. American Journal of Psychiatry 2006;163:2080–9.
Henderson R, Diggle P and Dobson A. Joint modeling of longitudinal measurements and event time data. Biostatistics 2000;1:465–80.
van den Oord EJ, Adkins DE, McClay J, Lieberman J and Sullivan PF. A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. Schizophrenia Research 2009;107:13–21.

Reference Title: References

Reference Type: reference-list

Eisenberg L. The social imperatives of medical research. Science 1977;198:1105–10.
Heres S, Davis J, Maino K, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. American Journal of Psychiatry 2006;163:185–94.
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209–23.
Essock SM, Covell NH, Davis SM, et al. Effectiveness of switching antipsychotic medications. American Journal of Psychiatry 2006;163:2090–5.
Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: A CATIE study. American Journal of Psychiatry 2007;164:415–27.
McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry 2006;163:600–10.
Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry 2006;163:611–22.
Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials. American Journal of Psychiatry 2001;158:518–26.
Davis JM, Chen N and Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 2003;60:553–64.
Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. British Medical Journal 2000;321:1371–6.
Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry 2009;166:152–63.
Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 1999;35:51–68.
Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: A systematic review and meta-analysis. Lancet 2003;361:1581–9.
Rosenheck RA, Davis VG, Davis SM, et al. Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. Schizophrenia Research 2009;113:12–8.

Reference Title: References

Reference Type: reference-list

Davis JM, Chen N and Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 2003;60:553–64.
Revicki DA, Luce BR, Weschler JM, Brown RE and Adler MA. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hospital & Community Psychiatry 1990;41:850–4.
Reid WH and Mason M. Psychiatric hospital utilization in patients treated with clozapine for up to 4.5 years in a state mental health care system. Journal of Clinical Psychiatry 1998;59:189–94.
Hamilton SH, Revicki DA, Edgell ET, Genduso LA and Tollefson G. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia – results from a randomized clinical trial. Pharmacoeconomics 1999;15:469–80.
Essock SM, Frisman LK, Covell NH and Hargreaves W. Cost-effectiveness of clozapine compared with conventional antipsychotic medications for patients in State Hospitals Archives of General Psychiatry 2000;5:987–94.
Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in the treatment of hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. New England Journal of Medicine 1997;337:809–15.
Rosenheck RA, Perlick D, Bingham S, et al. for the Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: A randomized controlled trial. Journal of the American Medical Association 2003; 290:2693–702.
Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of effect on quality of life of second-generation versus first-generation antipsychotic drugs in schizophrenia: Cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Archives of General Psychiatry 2006;63:1079–87.
Duggan M. Do new prescription drugs pay for themselves? The case of second-generation antipsychotics. Journal of Health Economics 2005;24:1–31.
Polsky D, Doshi JA, Bauer MS, et al. Clinical trial-based cost-effectiveness analyses of antipsychotic use. American Journal of Psychiatry 2006;163:2047–56.
Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development. Schizophrenia Bulletin 2003;29:15–31.
Stinnett AA and Mullahy J. Net health benefits: A new frame work for the analysis of uncertainty in cost-effectiveness analysis. Medical Decision Making 1998;18:(Suppl):S65–S80.
Gold MR, Siegel JE, Russell LB and Weinstein MC. Cost Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
Medical Economics Company. Drug Topics Red Book. Montvale, NJ: Medical Economics Company; 1999.
Department of Health and Human Services, Office of Inspector General (2005) Medicaid Drug Price Comparisons: Average Manufacturer Price to Published Prices (http://oig.hhs.gov/oei/reports/oei-03–05–00200.pdf, accessed on 23 November, 2005).
Rosenheck RA, Leslie DL and Sernyak ME. From clinical trials to real-world practice: Use of atypical antipsychotic medication nationally in the Department of Veterans Affairs. Medical Care 2001;39:302–8.
Thompson Medstat Group. Marketscan Communical Claims and Encounters Database. Ann Arbor, MI: The Thompson Medstat Group; 2002.
Bureau of Labor Statistics, US Department of Labor. 2004–05 Edition, Occupational Outlook Handbook, Bulletin 2540. Washington, DC: US Department of Labor; 2005.
National Association of State Mental Health Program Directors. Table 19: SMNHA Mental Health—Controlled Expenditures Per Inpatient Day, All Civil (Voluntary and Involuntary) Patients in State Psychiatric Hospitals Receiving Mental Health Services by Age and State, FY 2002. Alexandria, VA: National Association of State Mental Health Program Directors; 2002.
Grabowski DC, Feng Z, Intrator O and Mohr V. Recent trends in state nursing home payment policies. Health Affairs (Millwood) Web Exclusives 2004;4:W4–363–73.
US Department of Health and Human Services. June 18. The ADSS Cost Study: Costs of Substance Abuse Treatment in the Specialty Sector. Washington, DC: US Department of Health and Human Services; 2004.
Kasprow WJ, Rosenheck R, DiLella D, Cavallaro L, Harelik N. Health Care for Homeless Veterans Programs: The Seventeenth Annual Report. West Haven, CT: US Department of Veterans Affairs, North East Program Evaluation Center, VA Connecticut Health Care System; 2004.
Barnett PG. Review of methods to determine VA health care costs. Medical Care 1999;37(Suppl):AS9–AS17.
Greenberg G and Rosenheck RA. National Mental Health Program Performance Monitoring System: Fiscal Year 2002 Report. West Haven, CT: Northeast Program Evaluation Center; 2003.
Neale M, Rosenheck R, Martin A, Morrissey J and Castrodonatti J. Mental Health Intensive Case Management (MHICM): The Sixth National Performance Monitoring Report: FY 2003. West Haven, CT: Northeast Program Evaluation Center; 2004.
Resnick S, Rosenheck RA, Corwel L and Medak S. Seventh Progress Report on the Compensated Work Therapy/Veterans Industries Program. Fiscal Year 2003. West Haven, CT: Northeast Program Evaluation Center; 2004.
Frisman LK and Rosenheck RA. How transfer payments are treated in cost-effectiveness and cost-benefit analysis. Administration and Policy in Mental Health 1996;23:533–46.
US Department of Justice. In: K. Maguire and T. Flanagan, eds. Office of Justice Programs, Bureau of Justice Statistics Sourcebook of Criminal Justice Statistics–1990 (NCJ-130580). Washington, DC: USGPO; 1991.
Lenert L, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative syndrome scale scores. Schizophrenia Research 2004;71:155–65.
Lenert L, Sturly AP and Rupnow M. Toward improved methods for measurement of utility: Automated repair of errors in utility elicitations. Medical Decision Making 2003;23:1–9.
Mohr PE, Cheng CM, Claxton K, et al. The heterogeneity of schizophrenia in disease states. Schizophrenia Research 2004;71:83–95.
Kay SR, Fiszbein A and Opler L. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13:261–76.
Rosenheck RA, Stroup S, Keefe R, et al. Measuring outcome priorities and incorporating preferences in mental health status assessment of people with schizophrenia. British Journal of Psychiatry 2005;187:529–36.
Heinrichs DW, Hanlon ET and Carpenter WT. The quality of life scale: An instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 1984;10:388–98.
Addington D, Addington J and Maticka-Tyndale E. A depression rating scale for schizophrenics. Schizophrenia Research 1996;3:247–51.
Barnes T. A rating scale for drug-induced akathisia. British Journal of Psychiatry 1989;131:672–6.
Guy W. Abnormal involuntary movements. In: W. Guy ed., ECDEU Assessment Manual for Psychopharmacology. (DHEW No. ADM 76–338) Rockville, MD: National Institute of Mental Health; 1976.
Simpson GM and Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica. Supplementum 1970;212:11–9.
Lehman A. A quality of life interview for the chronically mentally ill. Evaluation and Program Planning 1988;11:51–62.
Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800–2.
Tabachnick B and Fidell L. Using Multivariate Statistics (4th Edition). Boston, MA: Allen and Bacon; 2000.
Duan N. Smearing estimate: A nonparametric retransformation method. Journal of the American Statistical Association 1983;78:605–10.
Manning WG and Mullahy J. Estimating log models: To transform or not to transform? Journal of Health Economics 2001;20:461–94.
Neumann PJ. Using Cost-effectiveness Analysis to Improve Health Care. New York: Oxford University Press; 2005.
Briggs A and Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Economics 1998;7:723–40.
Hoch J, Briggs A and Willan A. Something old, something new, something borrowed, something blue: A framework for the marriage of health economics and cost effectiveness analysis. Health Economics 2002;11:415–30.
Rosenheck RA, Leslie D, Sindelar J, et al. Cost-effectiveness of second generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. American Journal of Psychiatry 2006;163:2080–9.
Cramer JA, Rosenheck R, Xu W, Henderson W, Thomas J and Charney D. Detecting improvement in quality of life and symptomatology in schizophrenia. Schizophrenia Bulletin 2001;27:227–35.
Correll CU, Leucht S and Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. American Journal of Psychiatry 2004;161:414–25.
Halliday J, Farrington S, Macdonald S, MacEwan T, Sharkey V and McCreadie R. Nithsdale Schizophrenia Surveys: Movement disorders. British Journal of Psychiatry 2002;181:422–7.
Lee PE, Sykora K, Gill SS, et al. Antipsychotic medication and drug-induced movement disorder: A population-based cohort study in older adults. Journal of the American Geriatric Society 2005;53:1374–9.
Rochon PA, Stukel TA, Sykora K, et al. Atypical antipsychotics and parkinsonism. Archives of Internal Medicine 2005;165:1882–8.
Woods S, Saksa JR, Walsh B, Sullivan MC, Morganstern H and Glazer W (under review). Tardive Dyskinesia in a Community Mental Health Center: 2000–2005.
Rosenheck RA. Considerations for evaluating the cost-effectiveness of reducing tardive dyskinesia with second generation antipsychotics. British Journal of Psychiatry 2007;191:238–45.
Rosenheck RA, Swartz M, McEvoy J, et al. Changing perspectives on second generation antipsychotics: Reviewing the cost-effectiveness component of the CATIE trial. Expert Review of Pharmacoeconomics and Outcomes Research 2007;7:103–11.

Reference Title: References

Reference Type: reference-list

Norman RM, Malla AK, McLean T, et al. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatrica Scandinavica 2000;102:303–9.
Priebe S. Social outcomes in schizophrenia. British Journal of Psychiatry 2007;191:s15–s20.
Rosenheck RA, Stroup S, Keefe R, et al. Measuring outcome priorities and incorporating preferences in mental health status assessment of people with schizophrenia. British Journal of Psychiatry 2005;187:529–36.
Lambert M and Naber D. Current issues in schizophrenia: Overview of patient acceptability, functioning and quality of life. CNS Drugs 2004;18(Suppl):5–17.
Karow A and Naber D. Subjective well-being and quality of life under antipsychotic treatment. Psychopharmacology 2002;162:3–10.
Awad AG and Voruganti LNP. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 2004;18:877–93.
Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 1984;10:388–98.
Meltzer HY, Burnett S, Bastani B and Ramirez LF. Effects of six months of clozapine treatment on quality of life of chronic schizophrenic patients. Hospital & Community Psychiatry 1990;41:892–7.
Essock SM, Hargreaves WA, Covell NH, et al. Clozapine's effectiveness for patients in state hospitals: Results from a randomized trial. Psychopharmacology Bulletin 1996;32:683–97.
Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia: Department of Veterans Affairs cooperative study group on clozapine in refractory schizophrenia. New England Journal of Medicine 1997;337:809–15.
Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine vs. risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology 1997;17:407–18.
Hamilton SH, Revicki DA, Genduso LA, et al. Olanzapine vs. placebo and haloperidol: Quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 1998;18:41–9.
Jones PB, Barnes TRE, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1) Archives of General Psychiatry 2006;63:1079–87.
Swartz MS, Perkins DO, Stroup TS, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: Findings from the NIMH CATIE Study. American Journal of Psychiatry 2007;164:428–36.
Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development. Schizophrenia Bulletin 2003;29:15–31.
Swartz MS, Perkins DO, Stroup TS, et al. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial. Schizophrenia Bulletin 2003;29:33–43.
Davis SM, Koch GG, Davis CE, et al. Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies. Schizophrenia Bulletin 2003;29:73–80.
Keefe RS, Mohs RC, Bilder RM, et al. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: Development, methodology, and rationale. Schizophrenia Bulletin 2003;29:45–55.
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209–23.
Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia after discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry 2006;163:611–22.
McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine, quetiapine and risperidone in patients with chronic schizophrenia who failed prior atypical antipsychotic treatment. American Journal of Psychiatry 2006;153:600–10.
Swartz MS, Wagner HR, Swanson JW, et al. Substance use in persons with schizophrenia: Baseline prevalence and correlates from the NIMH CATIE study. Journal of Nervous and Mental Disease 2006;194:164–72.
Swartz MS, Wagner HR, Swanson JW, et al. Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE Study. Psychiatric Services 2006;57:1110–6.
Keefe RS, Bilder RM, Harvey PD, et al. Baseline neurocognitive deficits in the CATIE Schizophrenia Trial. Neuropsychopharmacology 2006;4:1–14.
Keefe RS, Bilder RM, Harvey PD, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia. Archives of General Psychiatry 2007;64:633–47.
Rosenheck R, Leslie D, Sindelar J, et al. Cost-effectiveness of first and second generation antipsychotics in the treatment of chronic schizophrenia. American Journal of Psychiatry 2006;163:2080–9.
Tracy K, Adler LA, Rotrosen J, et al. Interrater reliability issues in multicenter trials. Part I: Theoretical concepts and operational procedures in VA Cooperative Study #394. Psychopharmacology Bulletin 1997;33:53–57.
Kay SR, Fiszbein A and Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13:261–76.
Guy W. ECDEU Assessment Manual for Psychopharmacology – Revised (DHEW Publ No. ADM 76–338). Rockville, MD: U.S. Department of Health, Education, and Welfare. Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. pp 218–22.
Drake RE, Osher FC, Noordsy DL, et al. Diagnosis of alcohol use disorders in schizophrenia. Schizophrenia Bulletin 1990;16:57–67.
Addington D, Addington J, Maticka-Tyndale E, et al. Reliability and validity of a depression rating scale for schizophrenics. Schizophrenia Research 1992;6:201–8.
Hogan T, Awad AG and Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity. Psychological Medicine 1983;13:177–83.
Ware J Jr, Kosinski M and Keller SD. A 12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity. Medical Care 1996;34:220–33.
Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800–802.
Resnick SG, Rosenheck RA, Canive J, et al. Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. The Journal of Behavioral Health Services & Research 2008;35:215–25.
Tuunainen A, Wahlbeck K and Gilbody SM. Newer atypical antipsychotic medication in comparison to clozapine: A systematic review of randomised trials. Schizophrenia Research 2002;56:1–10.
Wahlbeck K, Cheine M and Essali MA. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews 2000;2:CD000059.
Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia: Cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Archives of General Psychiatry 2006;63:1079–87.
Pinikahana J, Happell B, Hope J, et al. Quality of life in schizophrenia: A review of the literature from 1995 to 2000. International Journal of Mental Health Nursing 2002;11:103–11.
Siegel SJ, Irani F, Brensinger CM, et al. Prognostic variables at intake and long-term level of function in schizophrenia. American Journal of Psychiatry 2006;163:433–41.
Hafner H. Gender differences in schizophrenia. Psychoneuroendocrinology 2003;28(Suppl 2):17–54.
Carter CS. Understanding the glass ceiling for functional outcome in schizophrenia Am J Psychiatry 2006;163:356–358.
Carpenter WT Jr. Targeting schizophrenia research to patient outcomes. American Journal of Psychiatry 2006;163:353–5.
Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The schizophrenia patient outcomes research team (PORT): Updated treatment recommendations 2003. Schizophrenia Bulletin 2004;30:193–217.
Lehman AF, Lieberman JA, Dixon LB, et al. American Psychiatric Association. Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry 2004;161(Suppl):1–56.

Reference Title: References

Reference Type: reference-list

Saykin AJ, Gur RC, Gur RE, et al. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Archives of General Psychiatry 1991;48:618–24.
Braff DL, Heaton R, Kuck J, et al. The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogeneous Wisconsin Card Sorting Test results. Archives of General Psychiatry 1991;48:891–8.
Brickman AM, Paul RH, Cohen RA, et al. Category and letter verbal fluency across the adult lifespan: Relationship to EEG theta power. Archives of Clinical Neuropsychology 2005;20:561–73.
Saykin AJ, Shtasel DL, Gur RE, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Archives of General Psychiatry 1994;51:124–31.
Davidson M, Reichenberg A, Rabinowitz J, et al. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. American Journal of Psychiatry 1999;156:1328–35.
Reichenberg A, Weiser M, Rapp MA, et al. Elaboration on premorbid intellectual performance in schizophrenia: Premorbid intellectual decline and risk for schizophrenia. Archives of General Psychiatry 2005;62:1297–304.
Fuller R, Nopoulos P, Arndt S, et al. Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance. American Journal of Psychiatry 2002;159:1183–9.
Heinrichs RW and Zakzanis KK. Neurocognitive deficit in schizophrenia: A quantitative review of the evidence. Neuropsychology 1998;12:426–45.
Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: Initial characterization and clinical correlates. American Journal of Psychiatry 2000;157:549–59.
Keefe RSE, Seidman LJ, Christensen BK, et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: A randomized, double-blind trial of olanzapine versus low doses of haloperidol. American Journal of Psychiatry 2004;161:985–95.
Gold JM, Queern C, Iannone VN, et al. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: Sensitivity, reliability, and validity. American Journal of Psychiatry 1999;156:1944–50.
Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry 1996;153:321–30.
Harvey PD, Howanitz E, Parrella M, et al. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: A comparison across treatment sites. American Journal of Psychiatry 1998;155:1080–6.
Keefe RS and Harvey PD. Implementation considerations for multi-site clinical trials with cognitive neuroscience tasks. Schizophrenia Bulletin 2008;34:656–63.
Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. New England Journal of Medicine 2006;355:1525–38.
Jastak S and Wilkinson GS. Wide Range Achievement Test-Revised 3. Wilmington, DE: Jastak Associates; 1993.
Mohs RC. Assessing cognitive function in schizophrenics and patients with Alzheimer's disease. Schizophrenia Research 1995;17:115–21.
Davidson M and Keefe RK. Cognitive impairment as a target for pharmacological treatment in schizophrenia. Schizophrenia Research 1995;17:123–9.
Keefe RS, Silva SG, Perkins DO, et al. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis. Schizophrenia Bulletin 1999;25:201–22.
Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS consensus cognitive battery: Part 1. Test selection, reliability, and validity. American Journal of Psychiatry 2008;165:203–13.
Keefe RS, Bilder RM, Harvey PD, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 2006;31:2033–46.
Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria. Biological Psychiatry 2004;56:301–7.
Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York: Academic Press; 1977.
Nuechterlein KH, Barch DM, Gold JM, et al. Identification of separable cognitive factors in schizophrenia. Schizophrenia Research 2004;72:29–39.
Keefe RSE, Seidman LJ, Christensen BK, et al. Two-year neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biological Psychiatry 2006;59:97–105.
Kern RS, Green MF, Marshall BD Jr, et al. Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients. Biological Psychiatry 1998;44:726–32.
Kivircik Akdede BB, Alptekin K, Kitis A, Arkar H and Akvardar Y. Effects of quetiapine on cognitive functions in schizophrenia. Progress in Neuro-psychopharmacology & Biological Psychiatry 2005;29:233–8.
Wagner M, Quednow BB, Westheide J, et al. Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: Randomized controlled trial of olanzapine vs. amisulpride. Neuropsychopharmacology 2005;30:381–90.
McGurk SR, Carter C, Goldman R, et al. The effects of clozapine and risperidone on spatial working memory in schizophrenia. American Journal of Psychiatry 2005;162:1013–6.
Harvey PD, Meltzer H, Simpson GM, et al. Improvements in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophrenia Research 2004;66:101–13.
McGurk SR, Lee MA, Jayathilake K and Meltzer HY. Cognitive effects of olanzapine treatment in schizophrenia. Medscape General Medicine 2004;6:27.
Harvey PD, Green MF, McGurk SR, et al. Changes in cognitive functioning with risperidone and olanzapine treatment: A large-scale, double-blind, randomized study. Psychopharmacology 2003;169:404–11.
Harvey PD, Napolitano JA, Mao L and Gharabawi G. Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. International Journal of Geriatric Psychiatry 2003;18:820–9.
Harvey PD, Siu CO and Romano S. Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology 2003;172:324–32.
Stip E, Remington GJ, Dursun SM, et al. Canadian multicenter trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine. Journal of Clinical Psychopharmacology 2003;23:400–4.
Sharma T, Hughes C, Soni W, et al. Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia. Psychopharmacology 2003;169:398–403.
Velligan DI, Prihoda TJ, Sui D, et al. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. Journal of Clinical Psychiatry 2003;64:524–31.
Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. American Journal of Psychiatry 2002;159:1018–28.
Good KP, Kiss I, Buiteman C, et al. Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: An interim analysis. British Journal of Psychiatry 2002;181:45–9.
Vaiva G, Thomas P, Llorca PM, et al. SPECT imaging, clinical features, and cognition before and after low doses of amisulpride in schizophrenic patients with the deficit syndrome. Psychiatry Research 2002;115:37–48.
Velligan DI, Newcomer J, Pultz J, et al. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophrenia Research 2002;53:239–48.
Chua L, Chong SA, Pang E, Ng VP and Chan YH. The effect of risperidone on cognitive functioning in a sample of Asian patients with schizophrenia in Singapore. Singapore Medical Journal 2001;42:243–6.
Fleming K, Thyrum P, Yeh C, et al. Cognitive improvement in psychotic subjects treated with “seroquel” (Quetiapine Fumarate): An exploratory study. Journal of Clinical Psychopharmacology 2001;21:527–9.
Potkin SG, Fleming K, Jin Yi, et al. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. Journal of Clinical Psychopharmacology 2001;21:479–83.
Purdon SE, Labelle A and Boulay L. Neuropsychological change in schizophrenia after 6 weeks of clozapine. Schizophrenia Research 2001;48:57–67.
Purdon SE, Malla A, Labelle A and Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. Journal of Psychiatry & Neuroscience 2001;26:137–49.
Smith RC, Infante M, Singh A, et al. The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia. International Journal of Neuropsychopharmacology 2001;3:239–50.
Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone and haloperidol. The Canadian Collaborative Group for research in schizophrenia. Archives of General Psychiatry 2000;57:249–58.
Lee MA, Jayathilake K and Meltzer HY. A comparison of the effect of clozapine with typical neuroleptics on cognitive function on neuroleptic responsive schizophrenia. Schizophrenia Research 1999;37:1–11.
Galletly CA, Clark CR, McFarlane AC and Weber DL. Effects of clozapine for non-treatment-resistant patients with schizophrenia. Psychiatric Services 1999;50:101–3.
Kern RS, Green MF, Barringer MD, et al. Risperidone versus haloperidol on secondary memory: Can newer medications aid learning? Schizophrenia Bulletin 1999;25:223–32.
Manschreck TC, Redmond DA, Candela SF and Maher BA. Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia. The Journal of Neuropsychiatry and Clinical Neurosciences 1999;11:481–9.
Meltzer HY and McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin 1999;25:233–55.
Rossi A, Mancini F, Stratta P, et al. Risperidone, negative symptoms and cognitive deficit in schizophrenia: An open study. Acta Psychiatrica Scandinavica 1997;95:40–3.
Serper MR and Chou JCY. Novel neuroleptics improve attentional functioning in schizophrenia patients: Ziprasidone and aripiprazole. CNS Spectrums 1997;2:56–9.
Fujii DE, Ahmed I, Jokumsen M, et al. The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients. The Journal of Neuropsychiatry and Clinical Neurosciences 1997;9:240–5.
Hoff AL, Faustman WO, Wieneke M, et al. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology 1996;15:361–9.
Lee MA, Thompson P and Meltzer H. Effects of clozapine on cognitive function in schizophrenia. Journal of Clinical Psychiatry 1994;55:82–7.
Buchanan RW, Holstein C and Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biological Psychiatry 1994;36:717–25.
Hagger C, Buckley P, Kenny JT, et al. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biological Psychiatry 1993;34:702–12.
Harvey PD and Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. American Journal of Psychiatry 2001;158:176–84.
Woodward ND, Purdon SE, Meltzer HY, et al. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. International Journal of Neuropsychopharmacology 2005;8:457–72.
Carpenter WT and Gold JM. Another view of therapy for cognition in schizophrenia. Biological Psychiatry 2002;51:969–71.
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209–23.
Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry 2007;64:633–47.
Rosenheck RA. Open forum: Effectiveness versus efficacy of second-generation antipsychotics: Haloperidol without anticholinergics as a comparator. Psychiatric Services 2005;56:85–92.
Hoyberg OJ, Fensbo C, Remvig J, et al. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatrica Scandinavica 1993;88:395–402.
Fruensgaard K, Wollenberg J, Hansen KM, Fensbo C and Sihm F. Loxapine versus perphenazine in psychotic patients. A double-blind, randomized, multicentre trial. Current Medical Research and Opinion 1978;5:601–7.
Van Putten T, Marder SR, Wirshing WC, et al. Neuroleptic plasma levels. Schizophrenia Bulletin 1991;17:197–216.
Sweet RA, Pollock BG, Mulsant, et al. Pharmacologic profile of perphenazine's metabolites. Journal of Clinical Psychopharmacology 2000;20:181–7.
Haro JM, Edgell ET, Jones PB, et al. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: Rationale, methods and recruitment. Acta Psychiatrica Scandinavica 2003;107:222–32.
Keefe RS, Sweeney JA, Gu H, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: A randomized, double-blind 52-week comparison. American Journal of Psychiatry 2007;164:1061–71.
Davidson M, Galderisi S, Weiser M, et al. Cognitive effects of antipsychotics drugs in first-episode schizophrenia and schizophreniform disorder: A randomized, open-label clinical trial (EUFEST). American Journal of Psychiatry (In press).
Goldbert GE, Goldman RS, Burdick KE, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: Is it a practice effect? Archives of General Psychiatry 2007;64:1115–22.
Keefe RS, Malhotra AK, Meltzer H, et al. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: A 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 2008;33:1217–28.
Castner SA, Williams GV, Goldman-Rakic PS. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 2000;287:2020–2.
Robbins TW. The 5-choice serial reaction time task: Behavioural pharmacology and functional neurochemistry. Psychopharmacology 2002;163:362–80.
Harvey PD, Moriarty PJ, Serper MR, et al. Practice-related improvement in information processing with novel antipsychotic treatment. Schizophrenia Research 2000;46:139–48.
Harvey PD, Rabinowitz J, Eerdekens M, et al. Treatment of cognitive impairment in early psychosis: A comparison of risperidone and haloperidol in a large long-term trial. American Journal of Psychiatry 2005;162:1888–95.
Buchanan RW, Davis M, Goff D, et al. A Summary of the FDA-NIMH-MATRICS workshop on clinical trial designs for neurocognitive drugs for schizophrenia. Schizophrenia Bulletin 2005;31:5–19.
Green MF, Nuechterlein KH, Kern RS, et al. Functional co-primary measures for clinical trials in schizophrenia: Results from the MATRICS psychometric and standardization study. American Journal of Psychiatry 2008;165:221–8.
McGurk SR, Twamley EW, Sitzer DI, et al. A meta-analysis of cognitive remediation in schizophrenia. American Journal of Psychiatry 2007;164:1791–802.
Medalia A, Revheim N and Casey M. The remediation of problem-solving skills in schizophrenia. Schizophrenia Bulletin 2001;27:259–67.

Reference Title: References

Reference Type: reference-list

Hunt MG. We Are What We Do: Examining Social Roles of People With Serious Mental Illness and Their Parents. Bowling Green, OH: Bowling Green State University; 2005.
Thoits PA. On merging identity theory and stress research. Social Psychology Quarterly 1991;54:101–12.
Bond GR, Resnick SG, Drake RE, Xie H, McHugo GJ and Bebout RR. Does competitive employment improve nonvocational outcomes for people with severe mental illness? Journal of Consulting and Clinical Psychology 2001;69:489–501.
Wolfensberger W. A brief overview of Social Role Valorization. Mental Retardation 2000;38:105–23.
Percudani M, Barbui C and Tansella M. Effect of second-generation antipsychotics on employment and productivity in individuals with schizophrenia. Pharmacoeconomics 2004;22:701–18.
Salkever D, Slade E and Karakus M. Differential effects of atypical versus typical antipsychotic medication on earnings of schizophrenia patients: Estimates from a prospective naturalistic study. Pharmacoeconomics 2006;24:123–39.
Malla AK, Norman RM, Scholten DJ, Zirul S and Kotteda V. A comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic. Journal of Clinical Psychiatry 2001;62:179–84.
Hamilton SH, Edgell ET and Revicki DA. Functional outcomes in schizophrenia: A comparison of olanzapine and haloperidol in a European sample. International Clinical Psychopharmacology 2000;15:245–55.
Bond GR, Kim HW, Meyer PS, et al. Response to vocational rehabilitation during treatment with first- or second- generation antipsychotics. Psychiatric Services 2004;55:59–66.
Meyer PS, Bond GR and Tunis SL. Comparison between the effects of atypical and traditional antipsychotics on work status for clients in a psychiatric rehabilitation program. Journal of Clinical Psychiatry 2002;63:108–16.
Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S and Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophrenia Research 2000;43:135–45.
Rosenheck R, Leslie D, Keefe R, et al. Barriers to employment for people with schizophrenia. American Journal of Psychiatry 2006;163:411–7.
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209–23.
Liang K and Zeger S. Regression analysis for correlated data. Annual Review of Public Health 1993;14:43–68.
Rosenheck RA, Leslie DL, Sindelar J, et al., Cost-effectiveness of second generation antipsychotics and perphenazine in the treatment of chronic schizophrenia. American Journal of Psychiatry 2006;163:2080–9.
Hochberg YA. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800–2.
McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry 2006;163:600–10.
Stroup TS, Lieberman JA, McEvoy JP, et al., Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry 2006;163:611–22.
Mueser K, Salyers M and Mueser P. A prospective analysis of work in schizophrenia. Schizophrenia Bulletin 2001;27:281–96.
Drew D, Drebing CE, Van Ormer A, et al. Effects of disability compensation on participation in and outcomes of vocational rehabilitation. Psychiatric Services 2001;52:1479–84.
Resnick SG, Rosenheck RA and Drebing CE. What makes vocational rehabilitation effective?: Program characteristics versus employment outcomes nationally in VA. Psychological Services 2006;3:239–48.
Rosenheck R, Frisman L and Sindelar J. Disability compensation and work among veterans with psychiatric and nonpsychiatric impairments. Psychiatric Services 1995;46:359–65.
O'Day B and Killeen M. Does U.S. federal policy support employment and recovery for people with psychiatric disabilities. Behavioral Science and the Law 2002;20:559–83.
MacDonald-Wilson KL, Rogers ES, Ellison ML, et al. A study of the social security work incentives and their relation to perceived barriers to work among persons with psychiatric disability. Rehabilitation Psychology 2003;48:301–9.
Polak P and Warner R. The economic life of seriously mentally ill people in the community. Psychiatric Services 1996;47:270–4.
Bond GR. Supported employment: Evidence for an evidence-based practice. Psychiatric Rehabilitation Journal 2004;27:345–58.
Bond GR, Drake RE, Becker DR. An update on randomized controlled trials of evidence-based supported employment. Psychiatric Services 2008;31:280–90.
Lehman AF, Steinwachs DM and the Survey Co-investigators of the PORT Project. Patterns of usual care for schizophrenia: Initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophrenia Bulletin 1998;24:11–20.
Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2003. Schizophrenia Bulletin 2004;30:193–217.
Becker DR, Lynde D and Swanson SJ. Strategies for state-wide implementation of supported employment: The Johnson & Johnson – Dartmouth Community Mental Health Program. Psychiatric Rehabilitation Journal 2008;31:296–9.
President's New Freedom Commission on Mental Health. Achieving the Promise: Transforming Mental Health Care in America. 2003: Washington, DC: President's New Freedom Commission on Mental Health; 2003. p. 98.
Resnick SG, Rosenheck RA and Lehman AF. An exploratory analysis of recovery and its correlates in people with schizophrenia. Psychiatric Services 2004;55:540–7.
Resnick SG and Rosenheck RA. Dissemination of supported employment in VHA. Journal of Rehabilitation Research and Development 2007;44:867–77.
Anthony WA and Blanch A. Supported employment for persons who are psychiatrically disabled: An historical and conceptual perspective. Psychosocial Rehabilitation Journal 1987;XI:5–23.
Rosenheck RA, Swartz M, McEvoy J, et al. Changing perspectives on second generation antipsychotics: Reviewing the cost-effectiveness component of the CATIE trial. Expert Review of Pharmacoeconomics and Outcomes Research 2007;7:103–11.
Drake RE, McHugo GJ, Becker DR, Anthony WA and Clark RE. The New Hampshire study of supported employment for people with severe mental illness. Journal of Consulting and Clinical Psychology 1996;2:391–9.

Reference Title: References

Reference Type: reference-list

Magliano L, Marasco C, Fiorillo A, et al. The impact of professional and social network support on the burden of families of patients with schizophrenia in Italy. Acta Psychiatrica Scandinavica 2002;106:291–8.
Lowyck B, De Hert M, Peeters E, et al. Burden on the family: A study of 120 relatives of schizophrenic patients in Belgium. Tijdschrift Voor Psychiatrie 2002;44:151–8.
Schene AH, Van Wijngaarden B and Koeter MWJ. Family caregiving in schizophrenia: Domains and distress. Schizophrenia Bulletin 1998;4:609–18.
McDonell MG, Short RA, Berry CM, et al. Burden in schizophrenia caregivers: Impact of family psychoeducation and awareness of patient suicidality. Family Practice 2003;42:91–103.
Angermeyer MC, Liebelt P and Matschinger H. Distress in parents of patients suffering from schizophrenia or affective disorders. Psychotherapie, Psychosomatik, Medizinische Psychologie 2001;51:255–60.
Ohaeri JU. Caregiver burden and psychotic patients' perception of social support in a Nigerian setting. Social Psychiatry and Psychiatric Epidemiology 2001;36:86–93.
Struening EL, Stueve A, Vine P, et al. Factors associated with grief and depressive symptoms in caregivers of people with serious mental illness. In: Greenley JR, ed. Research in Community Mental Health. Greenwich, CT: JAI Press Inc; 1995. pp 91–124.
Dyck DG, Short R, and Vitaliano PP. Predictors of burden and infectious illness in schizophrenia caregivers. Psychosomatic Medicine 1999;61:411–9.
Struening EL, Perlick DA, Link BG, Hellman F, Herman D and Sirey JA. The extent to which caregivers believe most people devalue consumers and their families. Psychiatric Services 2001;52:1633–8.
Link BG, Cullen FT, Struening EL, Shrout PE and Dohrenwend BP. A modified labeling theory approach to mental disorders: An empirical assessment. American Sociological Review 1989;54:400–23.
Perlick DA, Rosenheck RA, Miklowitz DJ, et al. Prevalence and correlates of burden among caregivers of patients with bipolar disorder enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Bipolar Disorders 2007;9:262–73.
Gallagher SK and Mechanic D. Living with the mentally ill: Effects on the health and functioning of other household members. Social Science & Medicine 1996;42:1691–701.
Mui AC. Perceived health and functional status among spouse caregivers of frail older persons. Journal of Aging and Health 1995;7:283–300.
Beach SR, Schulz R, Yee JL, et al. Negative and positive health effects of caring for a disabled spouse: Longitudinal findings from the caregiver health effects study. Psychology and Aging 2000;15:259–71.
Lieberman MA and Fisher L. The impact of chronic illness on the health and well-being of family members. Gerontologist 1995;35:94–102.
Sparks MB, Farran CJ, Donner E, et al. Wives, husbands, and daughters of dementia patients: Predictors of caregivers' mental and physical health. Scholarly Inquiry for Nursing Practice 1998;12:221–35.
Esterling BA, Kiecolt-Glaser JK, Bodnar JC, et al. Chronic stress, social support, and persistent alterations in the natural killer cell response to cytokines in older adults. Health Psychology 1994;13:291–8.
Haley WE, Levine EG, Brown SL, et al. Psychological, social, and health consequences of caring for a relative with senile dementia. Journal of the American Geriatrics Society 1987;35:405–11.
Kiecolt-Glaser JK, Marucha PT, Malarkey WB, et al. Slowing of wound healing by psychological stress. Lancet 1995;346:1194–6.
O'Reilly F, Finnan F, Allwright S, et al. The effects of caring for a spouse with Parkinson's disease on social, psychological and physical well-being. British Journal of General Practice 1996;46:507–12.
Pruchno RA and Potashnik SL. Caregiving spouses: Physical and mental health in perspective. Journal of the American Geriatrics Society 1989;37:697–705.
George LK and Gwyther LP. Caregiver well-being: A multidimensional examination of family caregivers of demented adults. Gerontologist 1986;26:253–9.
Dyck DG, Short R and Vitaliano PP. Predictors of burden and infectious illness in schizophrenia caregivers. Psychosomatic Medicine 1999;61:411–9.
Wolff N, Helminiak TW and Diamond RJ. Estimated societal costs of assertive community mental health care. Psychiatric Services 1995;46:898–906.
Falloon I, Boyd JL, McGill CW, et al. Family management in the prevention of morbidity of schizophrenia: Clinical outcome of a two-year longitudinal study. Archives of General Psychiatry 1985;42:887–96.
Falloon IR and Pederson J. Family management and the prevention of morbidity in schizophrenia: The adjustment of the family unit. British Journal of Psychiatry 1985;147:156–63.
Pilling S, Bebbington P, Kuipers E, et al. Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy. Psychological Medicine 2002;32:763–82.
Rosenheck RA, Cramer J, Jurgis G, et al. Clinical and psychopharmacological factors influencing family burden in refractory schizophrenia. Journal of Clinical Psychiatry 2000;61:671–6.
Perlick DA, Rosenheck R, Kaczynski R, Swartz MA, Canive JM, and Lieberman JA. Components and correlates of family burden in schizophrenia. Psychiatric Services 2006;57:1117–25.
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209–23.
Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development. Schizophrenia Bulletin 2003;29:15–31.
First MB, Gibbon M, Spitzer RL, and Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders—Research Version (SCID-I). New York: Biometrics Research; 1996.
Kay SR, Fiszbein A and Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13:261–76.
Addington D, Addington J and Maticka-Tyndale E. A depression rating scale for schizophrenics. Schizophrenia Research 1996;3:247–51.
Drake RE, Osher FC, Noordsy DL, et al. Diagnosis of alcohol use disorders in schizophrenia. Schizophrenia Bulletin 1990;16:57–67.
Heinrichs DW, Hanlon ET and Carpenter WT. The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 1984;10:388–98.
Lehman A. A quality of life interview for the chronically mentally ill. Evaluation and Program Planning 1988;11:51–62.
Barnes TR. A rating scale for drug induced akathisia. British Journal of Psychiatry 1989;154:672–6.
Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education, and Welfare; 1976.
Simpson GM and Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 1970;212:S11–S19.
Hogan TP, Awad AG and Eastwood MR. A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity. Psychological Medicine 1983;13:177–83.
Tessler RT and Gamache G. Toolkit for Evaluating Family Experiences With Severe Mental Illness. Cambridge, MA: Health Services Research Institute Evaluation Center; 1995.
SPSS for Windows, version 12.0. Chicago: SPSS; 2003.
Perlick DA, Wolff N, Miklowitz DJ, Menard K, Rosenheck RR; STEP-BD Family Experience Collaborative Study Group. Development of an integrated model of family burden in bipolar illness. The Journal of Mental Health Policy and Economics 2003;6.
Rosenheck R, Leslie D, Sindelar J, et al. Cost-effectiveness of second generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. American Journal of Psychiatry 2006;163:2080–9.
Dixon L, Stewart B, Burland J, Delahanty J, Lucksted A and Hoffman M. Pilot study of the effectiveness of the family-to family education program. Psychiatric Services 2001;52:965–67.
Dixon L, Lucksted A, Stewart B, et al. Outcomes of the peer-taught 12-week Family-to-Family Education Program for severe mental illness. Acta Psychiatrica Scandinavica 2004;109:207–15.
Cohen AN, Glynn SM, Murray-Swank AB, et al. The family forum: Directions for the implementation of family psychoeducation for severe mental illness. Psychiatric Services 2008;59:40–8.

Reference Title: References

Reference Type: reference-list

Rifkin A. Extrapyramidal side effects: A historical perspective. Journal of Clinical Psychiatry 1987;48(Suppl):3–6.
Delay J, Deniker P, Harl JM. [Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP).] Annales Médcio-Psychologiques 1952;110:112–7.
Sigwald J, Bouttier D, Raymondeau C and Piot C. Quatre cas de dyskinesie facio-bucco-linguo-masticatrice a evolution prolongee secondaire a un traitment pas les neuroleptiques. Revue Neurologique 1959;100:751–5.
Druckman R, Seelinger D and Thulin B. Chronic involuntary movements induced by phenothiazines. The Journal of Nervous and Mental Disorders 1962;135:69–76.
Van Putten T. Why do schizophrenic patients refuse to take their drugs?. Archives of General Psychiatry 1975;31:67–72.
Caroff S. The Neuroleptic malignant syndrome. Journal of Clinical Psychiatry 1980;41:79–83.
Kane J, Honigfeld G, Singer J and Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988;45:789–96.
Arvanitis LA and Miller BG. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biological Psychiatry 1997;42:233–46.
Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry 2003;60:681–90.
Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. American Journal of Psychiatry 1997;154:457–65.
Marder SR and Meibach RC. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry 1994;151:825–35.
Caroff SN, Mann SC, Campbell EC and Sullivan KA. Movement disorders associated with atypical antipsychotic drugs. Journal of Clinical Psychiatry 2002;63(Suppl. 4):12–9.
Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP and Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999;20:491–505.
Tarsy D, Baldessarini RJ and Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16:23–45.
Dossenbach M, Arango-Davila C, Silva Ibarra H, et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Journal of Clinical Psychiatry 2005;66:1021–30.
Kane JM, Woerner M and Lieberman J. Tardive dyskinesia: Prevalence, incidence, and risk factors. Journal of Clinical Psychopharmacology 1988;8(Suppl):52S–6S.
Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ and Caligiuri MP. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. Journal of the American Geriatrics Society 1999;47:716–9.
Glazer WM. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. Journal of Clinical Psychiatry 2000;61(Suppl. 4):21–6.
Correll CU, Leucht S and Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. American Journal of Psychiatry 2004;161:414–25.
Tenback DE, van Harten PN, Slooff CJ, Belger MA and van Os J. Effects of antipsychotic treatment on tardive dyskinesia: A 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. Journal of Clinical Psychiatry 2005;66:1130–3.
Leucht S, Pitschel-Walz G, Abraham D and Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 1999;35:51–68.
Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. Journal of Clinical Psychiatry. 2000;61(Suppl. 3):16–21.
Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophrenia Bulletin 1991;17:263–87.
Davis JM, Chen N and Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 2003;60:553–64.
Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. American Journal of Psychiatry 2006;163:2080–9.
Geddes J, Freemantle N, Harrison P and Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. British Medical Journal 2000;321:1371–6.
Leucht S, Wahlbeck K, Hamann J and Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: A systematic review and meta-analysis. Lancet 2003;361:1581–9.
Leucht S, Barnes TR, Kissling W, Engel RR, Correll C and Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory meta-analysis of randomized, controlled trials. American Journal of Psychiatry 2003;160:1209–22.
Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of clanzapine and haloperidol in the treatment of schizophrenia: A randomized controlled trial. Journal of the American Medical Association 2003;290:2693–702.
Hugenholtz GW, Heerdink ER, Stolker JJ, Meijer WE, Egberts AC and Nolen WA. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: Comparison with officially recommended doses. Journal of Clinical Psychiatry 2006;67:897–903.
Rosenheck R, Stroup S, Keefe RS, et al. Measuring outcome priorities and preferences in people with schizophrenia. British Journal of Psychiatry 2005;187:529–36.
Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 2006;63:1079–87.
Correll CU and Schenk EM. Tardive dyskinesia and new antipsychotics. Current Opinion in Psychiatry 2008;21:151–6.
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209–23.
Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development. Schizophrenia Bulletin 2003;29:15–31.
Davis SM, Koch GG, Davis CE and LaVange LM. Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies. Schizophrenia Bulletin 2003;29:73–80.
Simpson GM and Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica. Supplementum 1970;212:11–9.
Barnes TR. A rating scale for drug-induced akathisia. British Journal of Psychiatry 1989;154:672–6.
Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, MD: Department of Health; 1976.
Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal side effects of antipsychotics in a randomized trial. British Journal of Psychiatry 2008;193:279–88.
Schooler NR and Kane JM. Research diagnoses for tardive dyskinesia. Archives of General Psychiatry 1982;39:486–7.
Tarsy D. Neuroleptic-induced extrapyramidal reactions: Classification, description, and diagnosis. Clinical Neuropharmacology 1983;6(Suppl. 1):S9–26.
Gelenberg AJ. General principles of treatment of extrapyramidal syndromes. Clinical Neuropharmacology 1983;6(Suppl. 1):S52–6.
Simpson GM and Lindenmayer JP. Extrapyramidal symptoms in patients treated with risperidone. Journal of Clinical Psychopharmacology 1997;17:194–201.
Hirsch SR, Kissling W, Bauml J, Power A and O'Connor R. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. Journal of Clinical Psychiatry 2002;63:516–23.
Barnes TR and McPhillips MA. Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. British Journal of Psychiatry. Supplement 1999;(38):34–43.
Kane JM. Tardive dyskinesia. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. Nashville, TN: American College of Neuropsychopharmacology; 1995. pp 1485–95.
Tarsy D. History and definition of tardive dyskinesia. Clinical Neuropharmacology 1983;6:91–9.
Chakos MH, Alvir JM, Woerner MG, et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Archives of General Psychiatry 1996;53:313–9.
Beasley CM, Dellva MA, Tamura RN, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. British Journal of Psychiatry 1999;174:23–30.
Kane JM. Tardive dyskinesia circa 2006. American Journal of Psychiatry 2006;163:1316–8.
Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: A CATIE study. American Journal of Psychiatry 2007;164:415–27.
McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry 2006;163:600–10.
Stroup TS, Lieberman JA, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry 2006;163:611–22.
Miller DD, McEvoy JP, Davis SM, et al. Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial. Schizophrenia Research 2005;80:33–43.
Kay SR, Fiszbein A and Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13:261–76.
Kane JM, Leucht S, Carpenter D and Docherty JP. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: Methods, commentary, and summary. Journal of Clinical Psychiatry 2003;64(Suppl. 12):5–19.
Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Archives of General Psychiatry 2007;64:633–47.
Swartz MS, Perkins DO, Stroup TS, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: Findings from the NIMH CATIE study. American Journal of Psychiatry 2007;164:428–36.
Rosenheck R, Stroup S, Swartz M, et al. Dr. Rosenhack and colleagues reply. American Journal of Psychiatry 2007;164:678–80.
Kelsey JL, Whittemore AS, Evans AS and Thompson DS. Methods in Observational Epidemiology. New York: Oxford University Press; 1996.
Crane GE. Prevention and management of tardive dyskinesia. American Journal of Psychiatry 1972;129:466–7.
Kane JM, Woerner M, Borenstein M, Wegner J and Lieberman J. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacology Bulletin 1986;22:254–8.
Saltz BL, Woerner MG, Kane JM, et al. Prospective study of tardive dyskinesia incidence in the elderly. Journal of the American Medical Association 1991;266:2402–6.
Umbricht D and Kane JM. Medical complications of new antipsychotic drugs. Schizophrenia Bulletin 1996;22:475–83.

Reference Title: References

Reference Type: reference-list

Gerszten RE and Wang TJ. The search for new cardiovascular biomarkers. Nature 2008;451:949–52.
Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women [see comment]. Journal of the American Medical Association 2007;298:776–85.
Dhingra R, Gona P, Nam BH, et al. C-reactive protein, inflammatory conditions, and cardiovascular disease risk. The American Journal of Medicine 2007;120:1054–62.
Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories [see comment]. Circulation 1998;97:1837–47.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.
D'Agostino RB Sr, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: Results of a multiple ethnic groups investigation [see comment]. Journal of the American Medical Association 2001;286:180–7.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial.[see comment][summary for patients in Current Cardiology Reports 2002;4:486–7; PMID: 12379169]. Lancet 2002;360:7–22.
Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events [see comment]. New England Journal of Medicine 2002;347:1557–65.
Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New England Journal of Medicine 2000;342:836–43.
Boekholdt SM, Hack CE, Sandhu MS, et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: The EPIC-Norfolk prospective population study 1993–2003. Atherosclerosis 2006;187:415–22.
Cook NR, Buring JE and Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Annals of Internal Medicine 2006;145:21–9.
Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy [see comment]. New England Journal of Medicine 2005;352:20–8.
Epstein FH. Hyperglycemia: A risk factor in coronary heart disease. Circulation 1967;36:609–19.
Kannel WB and McGee DL. Diabetes and cardiovascular risk factors: The Framingham study. Circulation 1979;59:8–13.
Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction [see comment]. New England Journal of Medicine 1998;339:229–34.
Reaven GM. Banting lecture 1988: Role of insulin resistance in human disease. Diabetes 1988;37:1595–607.
de Vegt F, Dekker JM, Jager A, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. Journal of the American Medical Association 2001;285:2109–13.
Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: Findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004;173:309–14.
Kahn R, Buse J, Ferrannini E, et al. The Metabolic Syndrome: Time for a critical appraisal. Diabetes Care 2005;28:2289–304.
American Heart Association, National Heart Lung and Blood Institute; Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiology in Review 2005;13:322–7.
Wannamethee SG, Shaper AG, Lennon L, et al. Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Archives of Internal Medicine 2005;165:2644–50.
Girman CJ, Dekker JM, Rhodes T, et al. An exploratory analysis of criteria for the metabolic syndrome and its prediction of long-term cardiovascular outcomes: The Hoorn study. American Journal of Epidemiology 2005;162:438–47.
Lorenzo C, Williams K, Hunt KJ, et al. The National Cholesterol Education Program – Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007;30:8–13.
Assmann G, Guerra R, Fox G, et al. Harmonizing the definition of the metabolic syndrome: Comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European populations. American Journal of Cardiology 2007;99:541–8.
Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male Study. Circulation 1998;97:1029–36.
McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant [see comment][summary for patients in Annals of Internal Medicine 2003;139:I16; PMID: 14623638]. Annals of Internal Medicine 2003;139:802–9.
Smith DA. Treatment of the dyslipidemia of insulin resistance. Medical Clinics of North America 2007;91:1185–210.
Meyer JM and Koro CE. The effects of antipsychotic therapy on serum lipids: A comprehensive review. Schizophrenia Research 2004;70:1–17.
Allebeck P. Schizophrenia: A life-shortening disease. Schizophrenia Bulletin 1989;15:81–9.
Brown S. Excess mortality of schizophrenia. A meta-analysis. British Journal of Psychiatry 1997;171:502–8.
Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophrenia Research 2000;45:21–8.
Osby U, Correia N, Brandt L, et al. Time trends in schizophrenia mortality in Stockholm county, Sweden: Cohort study. British Medical Journal 2000;321:483–4.
Colton CW and Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Preventing Chronic Diseases 2006;3:1–14.
Saha S, Chant D and McGrath J. A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time? Archives of General Psychiatry 2007;64:1123–31.
Newcomer JW and Hennekens CH. Severe mental illness and risk of cardiovascular disease. Journal of the American Medical Association 2007;298:1794–6.
Meyer JM and Nasrallah HA, eds. Medical Illness and Schizophrenia. Washington, DC: American Psychiatric Press, Inc; 2003.
Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry 2004;161:1334–49.
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Journal of Clinical Psychiatry 2004;65:267–72.
Brown S, Birtwistle J, Roe L, et al. The unhealthy lifestyle of people with schizophrenia. Psychological Medicine 1999;29:697–701.
Druss BG, Bradford DW, Rosenheck RA, et al. Mental disorders and use of cardiovascular procedures after myocardial infarction [see comments]. Journal of the American Medical Association 2000;283:506–11.
Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE Schizophrenia Trial sample at baseline. Schizophrenia Research 2006;86:15–22.
Braceland FJ, Meduna LJ and Vaichulis JA. Delayed action of insulin in schizophrenia. Am J Psychiatry 1945;102:108–10.
Lorenz WF. Sugar tolerance in dementia praecox and other mental disorders. Archives of Neurology and Psychiatry 1922;8:184–96.
Meduna LJ, Gerty FJ and Urse VG. Biochemical disturbances in mental disorders: Anti-insulin effect of blood in cases of schizophrenia. Archives of Neurology and Psychiatry 1941;47:38–52 (correction, v. 47:1057).
Winkelmayer R. Diabetes mellitus in chronic mental patients. The Psychiatic Quarterly 1962;36:530–6.
Cohn TA, Remington G, Zipursky RB, et al. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: A preliminary report [erratum appears in Canadian Journal of Psychiatry 2006;51:552]. Canadian Journal of Psychiatry – Revue Canadienne de Psychiatrie 2006;51:382–6.
van Nimwegen LJM, Storosum JG, Blumer RME, et al. Hepatic insulin resistance in antipsychotic naive patients with schizophrenia, a detailed study of glucose metabolism with stable isotopes. Journal of Clinical Endocrinology and Metabolism 2008;93:572–7.
Mefferd RB, Labrosse EH, Gawienowski AM, et al. Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics. Journal of Nervous and Mental Disease 1958;127:167–79.
Efron HY and Balter AM. Relationship of phenothiazine intake and psychiatric diagnosis to glucose level and tolerance. Journal of Nervous and Mental Disease 1966;142:555–61.
Schwarz L and Munoz R. Blood sugar levels in patients treated with chlorpromazine. American Journal of Psychiatry 1968;125:253–5.
Clark ML, Ray TS, Paredes A, et al. Chlorpromazine in women with chronic schizophrenia: The effect on cholesterol levels and cholesterol-behavior relationships. Psychosomatic Medicine 1967;29:634–42.
Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 2005;19(Suppl. 1):1–93.
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209–23.
Heiskanen T, Niskanen L, Lyytikainen R, et al. Metabolic syndrome in patients with schizophrenia. Journal of Clinical Psychiatry 2003;64:575–9.
Cohn T, Prud'homme D, Streiner D, et al. Characterizing coronary heart disease risk in chronic schizophrenia: High prevalence of the metabolic syndrome. Canadian Journal of Psychiatry – Revue Canadienne de Psychiatrie 2004;49:753–60.
McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research 2005;80:19–32.
Dixon L, Postrado L, Delahanty J, et al. The association of medical comorbidity in schizophrenia with poor physical and mental health. Journal of Nervous and Mental Disease 1999;187:496–502.
Meyer JM, Nasrallah HA, McEvoy JP, et al. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research 2005;80:9–18.
Ware JE, Kosinski M and Keller SD. A 12-item Short-Form Health Survey (SF-12): Construction of scales and preliminary tests of reliability and validity. Medical Care 1996;32:220–33.
Kay SR, Fiszbein A and Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13:261–76.
Goff DC, Sullivan L, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE Study and matched controls. Schizophrenia Research 2005;80:45–53.
Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry 2006;163:611–22.
Weiden PJ, Daniel DG, Simpson GM, et al. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. Journal of Clinical Psychopharmacology 2003;23:1–6.
Weiden PJ, Newcomer JW, Loebel A, et al. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology 2008;33:985–95.
Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1. Schizophrenia Research 2008;101:273–86.
Eberly LE, Stamler J, Neaton JD, et al. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Archives of Internal Medicine 2003;163:1077–83.
Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. Journal of the American Medical Association 2007;298:299–308.
Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. Journal of the American Medical Association 2007;298:309–16.
Meyer JM, Davis VG, Goff DC, et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophrenia Research 2008;103:104–9.
Daumit GL, Goff DC, Meyer JM, et al. Antipsychotic effects on estimated 10 year coronary heart disease risk in the CATIE Schizophrenia Study. Schizophrenia Research 2008;105:175–87.
Meyer JM, McEvoy JP, Davis VG, et al. Inflammatory markers in schizophrenia: Comparing antipsychotic effects in phase 1 of the CATIE Schizophrenia Trial. Biological Psychiatry 2009 [Epub ahead of print].
Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: Results of a 10-year naturalistic study. Journal of Clinical Psychiatry 2005;66:1116–21.
Grundy SM, Brewer B, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433–38.

Reference Title: References

Reference Type: reference-list

Blanchard JJ, Brown SA, Horan WP and Sherwood AR. Substance use disorders in schizophrenia: Review, integration, and a proposed model. Clinical Psychology Review 2000;20:207–34.
Cantor-Graae E, Nordstrom LG and McNeil TF. Substance abuse in schizophrenia: A review of the literature and a study of correlates in Sweden. Schizophrenia Research 2001;48:69–82.
Dixon L. Dual diagnosis of substance abuse in schizophrenia: Prevalence and impact on outcomes. Schizophrenia Research 1999;35:S93–S100.
Goswami S, Mattoo SJ, Basu D and Singh G. Substance-abusing schizophrenics: Do they self-medicate? The American Journal on Addictions 2004;13:139–50.
Kavanagh DJ, McGrath J, Saunders JB, Dore G and Clark D. Substance misuse in patients with schizophrenia: Epidemiology and management. Drugs 2002;62:743–55.
Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J and Anthony JC. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Archives of General Psychiatry 1997;54:313–21.
McCreadie RG. Use of drugs, alcohol and tobacco by people with schizophrenia: Case-control study. British Journal of Psychiatry 2002;181:321–5.
Mueser KT, Drake RE and Wallace MA. Dual diagnosis: A review of etiological theories. Addictive Behaviors 1998;23:717–34.
Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. Journal of the American Medical Association 1990;264:2511–8.
Salyers MP and Mueser KT. Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophrenia Research 2001;48:109–23.
Haywood TW, Kravita HM, Grossman LS, Cavanaugh JL Jr, Davis JM and Lewis DA. Predicting the “revolving door” phenomenon among patient with schizophrenic, schizoaffective, and affective disorders. American Journal of Psychiatry 1995;151:856–61.
Swartz MS, Swanson JW, Hiday VA, Borum R, Wagner HR and Burns BJ. Violence and severe mental illness: The effects of substance abuse and nonadherence to medication. American Journal of Psychiatry 1998;155:226–31.
Swofford CD, Kasckow JW, Scheller-Gilkey G and Inderbitzin LB. Substance use: A powerful predictor of relapse in schizophrenia. Schizophrenia Research 1996;20:145–51.
Swanson J, Estroff S, Swartz M, et al. Violence and severe mental disorder in clinical and community populations: The effects of psychotic symptoms, comorbidity, and lack of treatment. Psychiatry 1997;60:1–22.
Goodman LA, Salyers MP, Mueser KT, et al. Recent victimization in women and men with severe mental illness: Prevalence and correlates. Journal of Traumatic Stress 2001;14:615–32.
Rosenberg SD, Goodman LA, Osher FC, et al. Prevalence of HIV, Hepatitis B and Hepatitis C in people with severe mental illness. American Journal of Public Health 2001;91:31–7.
Abram K and Teplin L. Co-occurring disorders among mentally ill jail detainees: Implications for public policy. The American Psychologist 1991;46:1036–44.
Swartz MS, Swanson JW and Hannon MJ. Detection of illicit substance use in persons with schizophrenia. Psychiatric Services 2003;54:891–5.
Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development. Schizophrenia Bulletin 2003;29:15–31.
Swartz MS, Wagner HR, Swanson JW, et al. Substance use in persons with schizophrenia: Baseline prevalence and correlates from the NIMH CATIE study. The Journal of Nervous and Mental Disease 2006;194:164–72.
Swartz MS, Wagner HR, Swanson JW, et al. Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. Psychiatric Services 2006;57:1110–6.
Swartz MS, Wagner HR, Swanson JW, et al. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: Results from the CATIE study. Schizophrenia Research 2008;100:39–52.
First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for Axes I and II DSM-IV Disorders-Patient Edition (SCID-I/P). New York: Biometrics Research Department, New York State Psychiatric Institute; 1996.
Drake R, Osher FC, Noordsy DL, Hurlbut SC, Teague GB and Beaudett MS. Diagnosis of alcohol use disorders in schizophrenia. Schizophrenia Bulletin 1990;16:57–67.
Addington D, Addington J and Schissel B. A depression rating scale for schizophrenics. Schizophrenia Research 1990;3:247–51.
Kay SR, Fiszbein A and Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13:261–76.
Heinrichs DW, Hanlon TE and Carpenter WT Jr. The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 1984;10:388–98.
US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. National Survey on Drug Use and Health. Washington, DC: HHS; 2006.
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209–23.

Reference Title: References

Reference Type: reference-list

Mullen PE. Schizophrenia and violence: From correlations to preventive strategies. Advances in Psychiatric Treatment 2006;12:239–48.
Walsh E, Buchanan A and Fahy T. Violence and schizophrenia: Examining the evidence. British Journal of Psychiatry 2002;180:490–5.
Swanson JW, Swartz MS, Van Dorn RA, et al. A national study of violent behavior in persons with schizophrenia. Archives of General Psychiatry 2006;63:490–9.
Swanson JW, Swartz MS, Van Dorn RA, et al. Comparison of antipsychotic drugs for reducing violence in persons with schizophrenia. British Journal of Psychiatry 2008;193:37–43.
Swanson JW, Van Dorn RA, Swartz MS, Smith A, Elbogen EB and Monahan J. Alternative pathways to violence in persons with schizophrenia: The role of childhood antisocial behavior problems. Law and Human Behavior 2008;32:228–40.
Bjorkly S. Psychotic symptoms and violence toward others – a literature review of some preliminary findings: Part 2. Hallucinations. Aggression and Violent Behavior 2002;7:605–15.
Bjorkly S. Psychotic symptoms and violence toward others – a literature review of some preliminary findings Part 1. Delusions. Aggression and Violent Behavior 2002;7:617–31.
Elbogen EB, Tomkins AJ, Pothuloori A and Scalora MJ. Documentation of violence risk factors in psychiatric facilities: An empirical examination. Journal of the American Academy of Psychiatry and the Law 2003;31:58–64.
Rutter M, Giller H and Hagell A. Antisocial Behavior by Young People. New York: Cambridge University Press; 1998.
Loeber R and Hay D. Key issues in the development of aggression and violence from childhood to early adulthood. Annual Review of Psychology 1997;48:371–410.
Hodgins S, Tiihonen J and Ross D. The consequences of conduct disorder for males who develop schizophrenia: Associations with criminality, aggressive behavior, substance use, and psychiatric services. Schizophrenia Research 2005;78:323–35.
Steadman HJ, Mulvey EP, Monahan J, et al. Violence by people discharged from acute psychiatric inpatient facilities and by others in the same neighborhoods. Archives of General Psychiatry 1998;55:393–401.
Susser M. Causal Thinking in the Health Sciences: Concepts and Strategies of Epidemiology. New York: Oxford University Press; 1973.
Fleiss JL, Williams JB and Dubro AF. The logistic regression analysis of psychiatric data. Journal of Psychiatric Research 1986;20:145–209.
Estroff S, Zimmer C, Lachicotte W and Benoit J. The influence of social networks and social support on violence by persons with serious mental illness. Hospital and Community Psychiatry 1994;45:669–79.
Swanson J, Swartz M, Estroff S, Borum R, Wagner R and Hiday V. Psychiatric impairment, social contact, and violent behavior: Evidence from a study of outpatient-committed persons with severe mental disorder. Social Psychiatry and Psychiatric Epidemiology 1998;33:S86–S94.
Swanson JW, Swartz MS and Elbogen EB. Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophrenia Bulletin 2004;30:3–20.
Herrera JN, Sramek JJ, Costa JF, Roy S, Heh CW and Nguyen BN. High potency neuroleptics and violence in schizophrenics. Journal of Nervous and Mental Disease 1988;176:558–61.
Volavka J, Czobor P, Nolan K, et al. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. Journal of Clinical Psychopharmacology 2004;24:225–8.

Reference Title: References

Reference Type: reference-list

Sullivan PF. Schizophrenia genetics: The search for a hard lead. Current Opinion in Psychiatry 2008;21:157–60.
Sullivan PF, Kendler KS and Neale MC. Schizophrenia as a complex trait: Evidence from a meta-analysis of twin studies. Archives of General Psychiatry 2003;60:1187–92.
Sullivan PF. The genetics of schizophrenia. PLoS Medicine 2005;2:e212.
Lohmueller KE, Pearce CL, Pike M, Lander ES and Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nature Genetics 2003;33:177–82.
Ioannidis JP. Commentary: Grading the credibility of molecular evidence for complex diseases. International Journal of Epidemiology 2006;35:572–8; discussion 593–6.
Lewis CM, Levinson DF, Wise LH, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder. II: Schizophrenia. American Journal of Human Genetics 2003;73:34–48.
Li D, Collier DA and He L. Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia. Human Molecular Genetics 2006;15:1995–2002.
Stefansson H, Sigurdsson E, Steinthorsdottir V, et al. Neuregulin 1 and susceptibility to schizophrenia. American Journal of Human Genetics 2002;71:877–92.
Straub RE, Jiang Y, MacLean CJ, et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. American Journal of Human Genetics 2002;71:337–48.
Millar JK, Wilson-Annan JC, Anderson S, et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Human Molecular Genetics 2000;9:1415–23.
Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007;316:889–94.
Risch N and Merikangas K. The future of genetic studies of complex human diseases. Science 1996;273:1516–7.
Frayling TM. Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nature Reviews. Genetics 2007;8:657–62.
Sullivan PF, Lin D, Tzeng JY, et al. Genomewide association for schizophrenia in the CATIE study: Results of stage 1. Molecular Psychiatry 2008;13:570–84.
Lencz T, Morgan TV, Athanasiou M, et al. Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Molecular Psychiatry 2007;12:572–80.
Kirov G, Zaharieva I, Georgieva L, et al. A genome-wide association study in 574 schizophrenia trios using DNA pooling. Molecular Psychiatry 2009;14:796–803.
Shifman S, Johannesson M, Bronstein M, et al. Genome-wide association identifies a common variant in the reelin gene that increases the risk of schizophrenia only in women. PLoS Genetics 2008;4:e28.
Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development. Schizophrenia Bulletin 2003;29:15–31.
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209–23.
Kay SR, Fiszbein A and Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13:261–76.
Sullivan PF, Keefe RS, Lange LA, et al. NCAM1 and neurocognition in schizophrenia. Biological Psychiatry 2007;61:902–10.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
First MB, Spitzer RL, Gibbon M and Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders–Administration Booklet. Washington DC: American Psychiatric Press Inc; 1994.
Skelly T, Pinheiro AP, Lange LA and Sullivan PF. Is rs7566605, a SNP near INSIG2, associated with body mass in a randomized clinical trial of antipsychotics in schizophrenia? Molecular Psychiatry 2007;12:321–2.
Herbert A, Gerry NP, McQueen MB, et al. A common genetic variant is associated with adult and childhood obesity. Science 2006;312:279–83.
Pinheiro AP, Keefe RS, Skelly T, et al. AKT1 and neurocognition in schizophrenia. The Austrailian and New Zealand Journal of Psychiatry 2007;41:169–77.
Campbell DB, Ebert PJ, Skelly T, et al. Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia. Biological Psychiatry 2008;63:32–41.
Campbell DB, Lange LA, Skelly T, Lieberman J, Levitt P and Sullivan PF. Association of RGS2 and RGS5 variants with schizophrenia symptom severity. Schizophrenia Research 2008;101:67–75.
Crowley JJ, Keefe RS, Perkins DO, Stroup TS, Lieberman JA and Sullivan PF. The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 2008;147B:1298–300.
Hall J, Whalley HC, Job DE, et al. A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms. Nature Neuroscience 2006;9:1477–8.
Law AJ, Lipska BK, Weickert CS, et al. Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5′ SNPs associated with the disease. Proceedings of the National Academy of Sciences of the United States of America 2006;103:6747–52.
Grossman I Sullivan PF, Walley N, et al. Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genetics in Medicine 2008;10:720–9.
Pritchard JK, Stephens M, Rosenberg NA and Donnelly P. Association mapping in structured populations. American Journal of Human Genetics 2000;67:170–81.
Balding DJ. A tutorial on statistical methods for population association studies. Nature Reviews. Genetics 2006;7:781–91.
Mah S, Nelson MR, Delisi LE, et al. Identification of the semaphorin receptor PLXNA2 as a candidate for susceptibility to schizophrenia. Molecular Psychiatry 2006;11:471–8.
Hennah W, Varilo T, Kestila M, et al. Haplotype transmission analysis provides evidence of association for DISC1 to schizophrenia and suggests sex-dependent effects. Human Molecular Genetics 2003;12:3151–9.
Cannon TD, Hennah W, van Erp TG, et al. Association of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory. Archives of General Psychiatry 2005;62:1205–13.
Shifman S, Bronstein M, Sternfeld M, et al. A highly significant association between a COMT haplotype and schizophrenia. American Journal of Human Genetics 2002;71:1296–302.
Manolio TA, Rodriguez LL, Brooks L, et al. New models of collaboration in genome-wide association studies: The Genetic Association Information Network. Nature Genetics 2007;39:1045–51.
Barrett JC and Cardon LR. Evaluating coverage of genome-wide association studies. Nature Genetics 2006;38:659–62.
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447:661–78.
Sullivan PF. Spurious genetic associations. Biological Psychiatry 2007;61:1121–16.
McClellan JM, Susser E and King MC. Schizophrenia: A common disease caused by multiple rare alleles. Br J Psychiatry 2007;190:194–9.

Reference Title: References

Reference Type: reference-list

Appelbaum P and Grisso T. The MacArthur Competence Assessment Tool-Clinical Research. Sarasota, FL: Professional Resource Press; 2001.
Carpenter WT Jr, Gold JM, Lahti AC, et al. Decisional capacity for informed consent in schizophrenia research. Archives of General Psychiatry 2000;57:533–8.
Moser DJ, Reese RL, Hey CT, et al. Using a brief intervention to improve decisional capacity in schizophrenia research. Schizophrenia Bulletin 2006;32:116–20.
Moser DJ, Reese RL, Schultz SK, et al. Informed consent in medication-free schizophrenia research. American Journal of Psychiatry 2005;162:1209–11.
Palmer BW, Nayak GV, Dunn LB, et al. Treatment-related decision-making capacity in middle-aged and older patients with psychosis: A preliminary study using the MacCAT-T and HCAT. The American Journal of Geriatric Psychiatry 2002;10:207–11.
Dunn LB, Nowrangi MA, Palmer BW, et al. Assessing decisional capacity for clinical research or treatment: A review of instruments. American Journal of Psychiatry 2006;163:1323–34.
Kim SY, Appelbaum PS, Swan J, et al. Determining when impairment constitutes incapacity for informed consent in schizophrenia research. British Journal of Psychiatry 2007;191:38–43.
Kovnick JA, Appelbaum PS, Hoge SK, et al. Competence to consent to research among long-stay inpatients with chronic schizophrenia. Psychiatric Services 2003;54:1247–52.
Kay SR, Fiszbein A and Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13:261–76.
Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophrenia Bulletin 1993;19:609–18.
Hogan TP, Awad AG and Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity. Psychological Medicine 1983;13:177–83.
Addington D, Addington J and Schissel B. A depression rating scale for schizophrenics. Schizophrenia Research 1990;3:247–51.
Stroup S, Appelbaum P, Swartz M, et al. Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research 2005;80:1–8.
Stroup TS and Appelbaum PS. Evaluation of “subject advocate” procedures in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study. Schizophrenia Bulletin 2006;32:147–52.
Baddeley A. Working memory. Science 1992;255:556–9.
Goldman-Rakic PS. Circuitry of primate prefrontal cortex and regulation of behavior by representative memory. In: F. Plum (ed.), Handbook of Physiology. The Nervous System. Higher Functions of the Brain. Bethesda, MD: The American Physiological Society; 1987. pp 373–417.
Gold JM, Carpenter C, Randolph C, et al. Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Archives of General Psychiatry 1997;54:159–65.
Park S and Holzman PS. Schizophrenics show spatial working memory deficits. Archives of General Psychiatry 1992;49:975–82.
Moser DJ, Schultz SK, Arndt S, et al. Capacity to provide informed consent for participation in schizophrenia and HIV research. American Journal of Psychiatry 2002;159:1201–7.
Jeste DV, Palmer BW, Appelbaum PS, et al. A new brief instrument for assessing decisional capacity for clinical research. Archives of General Psychiatry 2007;64:966–74.

Reference Title: References

Reference Type: reference-list

Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209–23.
Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. New England Journal of Medicine 2006;355:1525–38.
Bigos KL, Bies RR and Pollock BG. Population pharmacokinetics in geriatric psychiatry. American Journal of Geriatric Psychiatry 2006;14:993–1003.
Aravagiri M and Marder SR. Determination of olanzapine in plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to plasma level monitoring in schizophrenic patients. AAPS PharmSci 2002;4:Abstract W5016.
Aravagiri M, Marder SR and Pollock BG. Determination of ziprasidone in human plasma by liquid chromatography-electrospray tandem mass spectrometry and its application to plasma level determination in schizophrenia patients. Journal of Chromatography. B. Analytical Technologies in the Biomedical and Life Sciences 2007;847:237–44.
Sheiner LB, Rosenberg B and Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. Journal of Pharmacokinetics and Biopharmaceutics 1977;5:445–79.
Beal SL and Sheiner LB, eds. NONMEM Users Guides. Hanover, MD: GloboMax, LLC; 1989–98.
Bigos KL, Pollock BG, Coley KC, et al. Sex, race, and smoking impact olanzapine exposure. Journal of Clinical Pharmacology. 2008;48:157–65.
Callaghan JT, Bergstrom RF, Ptak LR and Beasley CM. Olanzapine: Pharmacokinetic and pharmacodynamic profile. Clinical Pharmacokinetics 1999;37:177–93.
Carrillo JA, Herráiz AG, Ramos SI, Gervasini G, Vizcaíno S and Benítez J. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. Journal of Clinical Psychopharmacology 2003;23:119–27.
Bozikasa VP, Papakostab M, Niopasb I, Karavatosa A and Mirtsou-Fidanic V. Smoking impact on CYP1A2 activity in a group of patients with schizophrenia European Neuropsychopharmacology 2004;14:39–44.
Ring BJ, Catlow J, Lindsay TJ, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine Journal of Pharmacology & Experimental Therapeutics 1996;276:658–66.
Bies RR, Bigos KL and Pollock BG. Gender differences in the pharmacokinetics and pharmacodynamics of antidepressants. The Journal of Gender-Specific Medicine 2003;6:12–20.
Bies RR, Bigos KL and Pollock BG. Gender and Antidepressants. Vol 2. New York: Elsevier Academic Press; 2004.
Gex-Fabry M, Balant-Gorgia AE and Balant LP. Therapeutic drug monitoring of olanzapine: The combined effect of age, gender, smoking, and comedication. Therapeutic Drug Monitoring 2003;25:46–53.
Kelly DL, Conley RR and Tamminga CA. Differential olanzapine plasma concentrations by sex in a fixed-dose study. Schizophrenia Research 1999;40:101–4.
Kelly DL, Richardson CM, Yu Y and Conley RR. Plasma concentrations of high-dose olanzapine in a double-blind crossover study. Human Psychopharmacology in Clinical Experience 2006;21:393–8.
Pollock BG, Wylie E, Stack JA, et al. Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women. Journal of Clinical Pharmacology 1999;39:936–40.
Krieger N. Stormy weather: Race, gene expression, and the science of health disparities. American Journal of Public Health 2005;95:2155–60.
Ingelman-Sundberg M, Daly AK and Nebert DW, eds. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. http://www.cypalleles.ki.se/. 2006.
Feng Y, Pollock BG, Reynolds C and Bies RR. Paroxetine pharmacokinetics in geriatric patients. AAPS PharmSci 2004:Abstract M1116.
Feng Y, Pollock BG, Ferrell RE, Kimak MA, Reynolds CF III and Bies RR. Paroxetine: Population pharmacokinetic analysis in late-life depression using sparse concentration sampling. British Journal of Clinical Pharmacology 2006;61:558–69.
Murayama N, Soyama A, Saito Y, et al. Six novel nonsynonymous CYP1A2 gene polymorphisms: Catalytic activities of the naturally occurring variant enzymes Journal of Pharmacology & Experimental Therapeutics 2004;308:300–6.
Feng Y, Pollock BG, Coley KC, et al. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. British Journal of Clinical Pharmacology 2008;66:629–39.
Aravagiri M, Marder SR, VanPutten T and Midha KK. Determination of risperidone in plasma by high-performance liquid chromatography with electrochemical detection: Application to therapeutic drug monitoring in schizophrenic patients. Journal of Pharmaceutical Sciences 1993;82:447–9.
Akaike H. A new look at the statistical model identification. IEEE Transactions on Automatic Control 1974;AC-19:716–23.
Green B and Duffull SB. Development of a dosing strategy for enoxaparin in obese patients. British Journal of Clinical Pharmacology 2003;56:96–103.
Aichhorn W, Weiss U, Marksteiner J, et al. Influence of age and gender on risperidone plasma concentrations. Journal of Psychopharmacology 2005;19:395–401.
Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R and Heykants J. Absorption, metabolism, and excretion of risperidone in humans. Drug Metabolism and Disposition 1993;21:1134–41.
Snoeck E, Van Peer A, Sack M, et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology (Berl) 1995;122:223–9.
Schneider L, Dagerman K and Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. Journal of the American Medical Association 2005;294:1934–43.
Human Cytochrome P450 (CYP) Allele Nomenclature Committee. http://www.imm.ki.se/CYPalleles/.
Kagimoto M, Heim M, Kagimoto K, Zeugin T and Meyer UA. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. The Journal of Biological Chemistry 1990;265:17209–14.
Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002;3:229–43.
Feng Y, Pollock BG, Ferrell RE, Kimak MA, Reynolds CF, III and Bies RR. Paroxetine: Population pharmacokinetic analysis in late-life depression using sparse concentration sampling. British Journal of Clinical Pharmacology 2006;61:558–69.
Feng Y, Pollock B, Reynolds C and Bies R. Paroxetine pharmacokinetics in geriatric patients. AAPS PharmSci 2004; Abstract M1116.
Saito M, Yasui-Furukori N, Nakagami T, Furukori H and Kaneko S. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. Journal of Clinical Psychopharmacology 2005;25:527–32.
Spina E, Avenoso A, Scordo MG, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction. Journal of Clinical Psychopharmacology 2002;22:419–23.
DeVane CL and Nemeroff CB. Clinical pharmacokinetics of quetiapine: An atypical antipsychotic. Clinical Pharmacokinetics 2001;40:509–22.
Tucker WE Jr. Preclinical toxicology of bupropion: An overview. Journal of Clinical Psychiatry 1983;44(Pt. 2):60–2.
Hesse LM, Sakai Y, Vishnuvardhan D, Li AP, von Moltke LL and Greenblatt DJ. Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: Comparison with rifampicin. The Journal of Pharmacy and Pharmacology 2003;55:1229–39.
Schroeder DH. Metabolism and kinetics of bupropion. Journal of Clinical Psychiatry 1983;44(Pt. 2):79–81.
Kimko HC, Reele SS, Holford NH and Peck CC. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clinical Pharmacology and Therapeutics 2000;68:568–77.
Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF and Bareggi SR. Clinical pharmacokinetics of atypical antipsychotics: A critical review of the relationship between plasma concentrations and clinical response. Clinical Pharmacokinetics 2007;46:359–88.
Nemeroff CB, Kinkead B and Goldstein J. Quetiapine: Preclinical studies, pharmacokinetics, drug interactions, and dosing. Journal of Clinical Psychiatry 2002;63(Suppl. 13):5–11.
Cheer SM and Wagstaff AJ. Quetiapine. A review of its use in the management of schizophrenia. CNS Drugs 2004;18:173–99.
Small JG, Hirsch SR, Arvanitis LA, Miller BG and Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Archives of General Psychiatry 1997;54:549–57.
Hasselstrom J and Linnet K. Quetiapine serum concentrations in psychiatric patients: The influence of comedication. Therapeutic Drug Monitoring 2004;26:486–91.
Thyrum PT, Wong YW and Yeh C. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2000;24:521–33.
Jaskiw GE, Thyrum PT, Fuller MA, Arvanitis LA and Yeh C. Pharmacokinetics of quetiapine in elderly patients with selected psychotic disorders. Clinical Pharmacokinetics 2004;43:1025–35.
Kimko HC, Reele SS, Holford NH and Peck CC. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clinical Pharmacology and Therapeutics 2000;68:568–77.
Eggert Hansen C, Rosted Christensen T, Elley J, et al. Clinical pharmacokinetic studies of perphenazine. British Journal of Clinical Pharmacology 1976;3:915–23.
Jerling M, Dahl ML, Aberg-Wistedt A, et al. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clinical Pharmacology and Therapeutics 1996;59:423–8.
Schering Corporation. Product Information: Trilafon(R), perphenazine. Kenilworth, NJ: Schering Corporation; 07/2002.
Wan YJ, Poland RE, Han G, et al. Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California. Pharmacogenetics 2001;11:489–99.
Leathart JB, London SJ, Steward A, Adams JD, Idle JR and Daly AK. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 1998;8:529–41.
Wennerholm A, Dandara C, Sayi J, et al. The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. Clinical Pharmacology and Therapeutics 2002;71:77–88.
Masimirembwa C, Persson I, Bertilsson L, Hasler J and Ingelman-Sundberg M. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: Association with diminished debrisoquine hydroxylase activity. British Journal of Clinical Pharmacology 1996;42:713–9.
Olesen OV and Linnet K. Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. British Journal of Clinical Pharmacology 2000;50:563–71.
Kroon LA. Drug interactions with smoking. American Journal of Health-System Pharmacy 2007;64:1917–21.
Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF and Bareggi SR. Clinical pharmacokinetics of atypical antipsychotics: A critical review of the relationship between plasma concentrations and clinical response. Clinical Pharmacokinetics 2007;46:359–88.
Perry PJ, Lund BC, Sanger T and Beasley C. Olanzapine plasma concentrations and clinical response: Acute phase results of the North American Olanzapine Trial. Journal of Clinical Psychopharmacology 2001;21:14–20.
Perry PJ, Sanger T and Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. Journal of Clinical Psychopharmacology 1997;17:472–7.
Lane HY, Guo SC, Hwang TJ, et al. Effects of olanzapine plasma concentrations on depressive symptoms in schizophrenia: A pilot study. Journal of Clinical Psychopharmacology 2002;22:530–2.
Fellows L, Ahmad F, Castle DJ, Dusci LJ, Bulsara MK and Ilett KP. Investigation of target plasma concentration-effect relationships for olanzapine in schizophrenia. Therapeutic Drug Monitoring 2003;25:682–9.
Mauri MC, Steinhilber CPC, Marino R, et al. Clinical outcome and olanzapine plasma levels in acute schizophrenia. European Psychiatry 2005;20:55–60.

Reference Title: References

Reference Type: reference-list

Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA and Lieberman JA. Effectiveness of switching antipsychotic medications. American Journal of Psychiatry 2006;163:2090–5.
Leucht S, Heres S, Hamann J and Kissling W. Pretrial medication bias in randomized antipsychotic drug trials. American Journal of Psychiatry 2007;164:1266; author reply -7.
Sullivan PF, Lin D, Tzeng JY, et al. Genomewide association for schizophrenia in the CATIE study: Results of stage 1. Molecular Psychiatry 2008;13:570–84.
Kim SY, Appelbaum PS, Swan J, et al. Determining when impairment constitutes incapacity for informed consent in schizophrenia research. British Journal of Psychiatry 2007;191:38–43.

Reference Title: References

Reference Type: reference-list

Simon GE, Psaty BM, Hrachovec JB, et al. Principles for evidence-based drug formulary policy. Journal of General Internal Medicine 2005;20:964–8.
Essock SM, Covell NH, Davis SM, et al. Effectiveness of switching antipsychotic medications. American Journal of Psychiatry 2006;163:2090–5.
Davis JM, Chen N and Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 2003;60:553–64.
Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet 2009;737:31–41.
Correll CU, Leucht S and Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. American Journal of Psychiatry 2004;161:414–25.
Hamilton SH, Revicki DA, Edgell ET, et al. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia – results from a randomized clinical trial. Pharmacoeconomics 1999;15:469–80.
Marder SR and Meibach RC. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry 1994;151:825–35.
Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. American Journal of Psychiatry 1997;154:457–65.
Csernansky JG, Mahmoud R and Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine 2002;346:16–22.
Carpenter WT and Thaker GK. Editorial: Evidence based therapeutics: Introducing the Cochrane Corner. Schizophrenia Bulletin 2007;33:633–4.
Geddes JR, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia – systematic overview and meta-regression analysis. British Medical Journal 2000;321:1371–6.
Huston P and Moher D. Redundancy, disaggregation, and the integrity of medical research. Lancet 1996;347:1024–6.
Rosenheck RA, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. Journal of the American Medical Association 2003;290:2693–702.
Rosenheck RA. Efficacy vs. effectiveness of second-generation antipsychotics: Haloperidol without prophylactic anticholinergics as a comparitor. Psychiatric Services 2005;56:85–92.
Hugenholtz GW, Heerdink ER, Stolker JJ, et al. Haloperidol dose when used as active comparitor in randomized controlled trials with atypical antipsychotics in schizophrenia: Comparison with officially recommended doses. Journal of Clinical Psychiatry 2006;67:897–903.
Davis JM, Chen N and Glick ID. Issues that may determine the outcome of antipsychotic trials: Industry sponsorship and extrapyramidal side effects. Neuropsychopharmacology 2007;33:971–5.
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209–23.
Jones PB, Barnes TRE, Davies L, et al. Randomized controlled trial of effect on quality of life of second-generation versus first-generation antipsychotic drugs in schizophrenia – CUtLASS1. Archives of General Psychiatry 2006;63:1079–87.
Davies LM, Lewis S, Jones PB, et al. Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. The British Journal of Psychiatry 2007;191:14–22.
Polsky D, Doshi JA, Bauer MS, et al. Clinical trial-based cost-effectiveness analyses of antipsychotic use. American Journal of Psychiatry 2006;163:2047–56.
Duggan M. Do new prescription drugs pay for themselves? The case of second-generation antipsychotics. Journal of Health Economics 2005;24:1–31.
Kane JM, Meltzer HY, Carson WH, et al. Aripiprazole for treatment-resistant schizophrenia: Results of a multicenter, randomized, double-blind, comparison study versus perphenazine. Journal of Clinical Psychiatry 2007;68:213–23.
Rosenheck RA, Leslie DL, Busch S, et al. Rethinking antipsychotic formulary policy. Schizophrenia Bulletin 2008;34:375–80.
Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet 2008;371:1085–97.
Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early onset schizophrenia and schizoaffective disorder: Findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. American Journal of Psychiatry 2008;165:1420–31.
Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry 2009;166:152–63.
Owens DC. What CATIE did: Some thoughts on implications deep and wide. Psychiatric Services 2008;59:530–3.
Rosenheck R, Craner J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on clozapine in refractory schizophrenia. New England Journal of Medicine 1997;337:809–15.
Breier A, Berg PH, Thakore JH, et al. Olanzapine versus ziprasidone: Results of a 28-week double blind study in patients with schizophrenia. American Journal of Psychiatry 2005;162:1879–87.
Freedman R, Carpenter WT, Davis JM, et al. The cost of drugs for schizophrenia. American Journal of Psychiatry 2006;163:2029–31.
American Diabetes Association (ADA), American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596–601.
Correll CU, Leucht S and Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. American Journal of Psychiatry 2004;161:414–25.
Swanson JW, Swartz MS, Van Dorn RA, et al. A national study of violent behavior in persons with schizophrenia. Archives of General Psychiatry 2006;63:490–9.
Rosenheck RA, Hoff RA, Steinwachs D, et al. Benchmarking treatment of schizophrenia: A comparison of service delivery by the national government and by state and local providers. Journal of Nervous and Mental Disease 2000;188:209–16.
Kelsey JL, Whittemore AS, Evans AS, et al. Methods in Observational Epidemiology. 2nd ed. New York: Oxford University Press; 1996. pp 88–9.
Last JM, ed. A Dictionary of Epidemiology. 3rd ed. New York: Oxford University Press; 1996.
Meltzer HY and Bobo WV. Interpreting the efficacy findings in the CATIE study: What clinicians should know. CNS Spectrum 2006;11(Suppl. 7):14–24.
Kane JM. Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Journal of Clinical Psychiatry 2006;76:831–2.
Tandon R and Constatine R. Avoiding EPS is key to realizing “atypical benefits”. Current Psychiatry 2006;5:35–45.
Rosack J. Experts say tread slowly when trying to interpret study results. Psychiatric News 2006;41:23.
Goode E. Leading drugs for psychosis come under scrutiny. NY Times May 20, 2003, p. A1.
Freedman R. The choice of antipsychotic drugs for schizophrenia. New England Journal of Medicine 2005;353:1286–8.
Ganguli R, Strassnig M. Are older antipsychotic drugs obsolete: No. British Medical Journal 2006;332:1345–6.
Lewis S and Lieberman JA. CATIE and CUtLASS: Can we handle the truth? British Journal of Psychiatry 2008;192:161–3.
Nasrallah H. The role of efficacy, safety, and tolerability in antipsychotic effectiveness: Practical implications of the CATIE schizophrenia trial. Journal of Clinical Psychiatry 2007;68(Suppl. 1):5–11.
Sharfstein S. Antipsychotics, economics and the press. Psychiatric News 2005;40:3.
New York Times. Editorial: Comparing schizophrenia drugs. New York Times, 2005 September 21. http://www.nytimes.com/2005/09/21/opinion/21wed3.html?ex=1183953600&en=1cadcb61b264f0c5&ei=5070.
Vedantam S. New antipsychotic drugs criticized Federal study finds no benefit over older, cheaper drug. Washington Post, September 20, 2005, A0.
Abramson J. Overdosed America: The Broken Promise of American Medicine. New York, NY: Harper Collins; 2004.
Angel M. The Truth About the Drug Companies: How They Deceive Us and What to do About It. New York, NY: Random House; 2004.
Avorn J. Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs. New York, NY: Knopf; 2004.
Kassirer J. On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health. New York, NY: Oxford University Press; 2004.
Moore TA, Buchanan RW, Buckley PF, et al. The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2006 update. Journal of Clinical Psychiatry 2007;68:1751–62.
Parks J, Radke A, Parker G, et al. Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. Schizophrenia Bulletin 2009;35:931–6.
Carpenter WT and Buchanan RW. Lessons to take home from CATIE. Psychiatric Services 2008;59:523–5.
Sernyak MJ, Leslie D and Rosenheck RA. Antipsychotic use in the treatment of outpatients with schizophrenia in the VA from fiscal years 1999 to 2006. Psychiatric Services 2008;59:567–9.
Cascade E and Kalali A. One of antipsychotics pre-and post dissemination of the CATIE data. Psychiatry 2007;4:21–3.
Citrome L, Jaffe A, Martello D, et al. Did CATIE influence antipsychotic use? Psychiatric Services 2008;59:476.
Ubel PA. Pricing Life: Why Its Time for Health Care Rationing. Cambridge, MA: MIT Press; 2001.
Domino ME and Swartz MS. Who are the new users of antipsychotic medications? Psychiatric Services 2008;59:507–14.
Briesacher BA, Limcangco MR, Simoni-Wastila L, et al. The quality of antipsychotic drug prescribing in nursing homes. Archives of Internal Medicine 2005;165:1280–5.
Schneider LS, Tariot PN, Dagerman KS, et al. CATIE-AD Study Group: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. New England Journal of Medicine 2006;355:1525–38.
Hoadley J. Cost Containment Strategies for Prescription Drugs: Assessing the Evidence in the Literature. Health Policy Institute. Georgetown University; 2005. http://www.kff.org/rxdrugs/7295.cfm.
Weisfeldt ML and Zieman SJ. Advances in the prevention and treatment of cardiovascular disease. Health Affairs (Millwood) 2007;26:25–37 (cf. p. 29).
Law MR, Ross-Degnan D and Soumerai SB. Effect of prior authorization on second-generation antipsychotic agents on pharmacy utilization and reimbursements. Psychiatric Services 2008;59:540–6.
Soumerai SB, Zhang F, Ross-Degnan D, et al. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Affairs (Millwood) 2008;27:w185–w195.
Duckworth K and Fitzpatrick MJ. NAMI perspective on CATIE: policy and research indications. Psychiatric Services 2008;59:537–40.
Covell NH, Finnerty MT and Essock SM. Implications for CATIE for mental health services researchers. Psychiatric Services 2008;59:526–9.
Frank RG. Policy toward second-generation antipsychotic drugs: A cautionary note. Psychiatric Services 2008;59:521–2.
Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically-ill. Journal of the American Medical Association 2004;291:2344–50.
Huskamp HA, Deverka PA, Epstein AM, et al. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children. Archives of General Psychiatry 2005;62:435–41.
Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS and Bollini P. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. New England Journal of Medicine 1994;331:650–5.
Polinski JM, Wang PS and Fischer MA. Medicaid's prior authorization program and access to atypical antipsychotic medications. Health Affairs (Millwood) 2007;26:759–60.
DeAngelis CD and Fontanarosa PB. Impugning the integrity of medical science: The adverse effects of industry influence. Journal of the American Medical Association 2008;299:1833–5.
Turner EH, Matthews AM, Linardatos E, Tell RA and Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine 2008;358:252–60.
Rennie D. Fair conduct and fair reporting of clinical trials. Journal of the American Medical Association 1999;282:1766–8.
Yan J. Experts disagree on impact of medicine, industry relationship. Psychiatric News 2008;43:1.
Peterson M. Our Daily Meds. New York: Sarah Crichton Books-Farrar, Straus and Giroux; 2008.